Navigation Links
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Date:12/17/2009

that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, including Medivation's dependence on the efforts of and funding by Pfizer and Astellas for the development of dimebon and MDV3100, respectively, the achievement of development, regulatory and commercial milestones under Medivation's collaboration agreements, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended September 30, 2009, filed with the SEC on November 4, 2009. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

SOURCE Medivation, Inc.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
2. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
3. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
4. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
5. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
6. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
8. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
11. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
(Date:9/1/2014)... shows on TV may be bad for your waistline, a ... while watching action films and programs than something less exciting, ... if you,re watching an action movie while snacking your mouth ... the Cornell Food and Brand Lab, said in a university ... is, the more you will eat." The study included ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 An operating ... a hospital for performing surgical operations. An operating room ... tables, surgical booms, operating room lights, imaging displays as ... a report by Transparency Market Research, a U.S.-based market ... to reach USD 4.5 billion by 2019. , ...
(Date:9/1/2014)... 01, 2014 The B-cell non-Hodgkin’s Lymphoma ... six major markets (the US, France, Italy, Germany, Spain ... $5.41 billion by 2018. , The competitive landscape in ... Germany, Spain and the UK is poised to undergo ... of the four largest B-cell NHL indications, which includes ...
(Date:9/1/2014)... 1 September 2014: Permanent atrial fibrillation (AF) doubles the ... research in more than 6 000 patients presented at ... The findings suggest that a simple clinical assessment of ... estimate stroke risk. , Ischaemic stroke is the second ... a million deaths and many more disabled patients each ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3
... ... will help you transform the way employees engage inside and outside of the workplace. ... Milwaukee, Wisc. (PRWEB) February 1, ... event “Aligning the Corporate and Personal Brand,” hosted by Loyola University in Chicago. ...
... who took the course were more likely to delay having ... who took abstinence-only sex education classes were more likely to ... study, some 662 black 6th- and 7th-grade students, ranging in ... 12, participated in classes held on Saturdays at four Philadelphia ...
... memory skills after 12 weeks of treatment, researchers report ... after a stroke may help repair the damaged brain ... Little has been shown to help the brain restore ... initial stroke treatment. But a University of Iowa study ...
... Surprise finding may have implications for labor anesthesia, orthopedics and ... One of the holy grails of local anesthesia is the ability ... not affecting motor function. Now, researchers at Children,s Hospital Boston have ... it proves to work in humans as well as it did ...
... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
... , Proposed projects will combat global ... Kiwanis International is searching for its next global cause, ... Service Project finalists: Global Network for Neglected Tropical Diseases for ... the Canadian Red Cross for their joint malaria proposal; and ...
Cached Medicine News:Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 3Health News:Antidepressants After Stroke May Boost Mental Ability 2Health News:Antidepressants After Stroke May Boost Mental Ability 3Health News:Anesthetic Approach Stops Pain Without Affecting Motor Function 2Health News:Anesthetic Approach Stops Pain Without Affecting Motor Function 3Health News:FDA Announces Safety Risk Associated with HIV Drug 2Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 2Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 3Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 4
Designated most popular model or size. Double-ended. 2 mm wide....
Designated most popular model or size. Slightly angled, 2 mm wide....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Desmarres Infant Retractor...
Medicine Products: